Solid-State Chemistry: A Technical Forum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solid-State Chemistry: A Technical Forum
Leading experts share insight on polymorphism and crystallization.


Pharmaceutical Technology
Volume 33, Issue 12, pp. 34-35, 65

References

1. ICH, Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (1999).

2. H.G. Brittain, Ed., Polymorphism in Pharmaceutical Solids (2nd edition, Informa Healthcare, London).

3. J. Haleblian and W. McCrone, J. Pharm. Sci., 58 (58), 911–929 (1969).

4. T.L. Threlfall, Analyst, 120 (10) 2435–2460 (1995).

5. D. Singhal D and W. Curatolo, Adv. Drug Delivery Rev. 56 (5) 335–347 (2004).

6. S.L. Price, Acc. Chem. Res. 42 (1) 117–126 (2009).

7. M.A. Neumann and M.A. Perrin, J. Phys. Chem. B, 109 (32), 15531–15541 (2005).

8. M.A. Neumann, J. Phys. Chem. B, 112 (32), 9810–9829 (2008).

9. M.A. Neumann, F.J.J. Leusen, and J. Kendrick, Angew. Chem. Int. Ed. 47 (13), 2427–2430 (2008).

10. G.M. Day et al., Acta Cryst. B 65 (2) 107–125 (2009).

11. S.R.Chemburkar et al., Org. Process Res. Dev. 4 (5), 413–417 (2000).

12. Y. Kobayashi et al., "Int. J. Pharm 193 (2), 137–146 (2000).

13. J. Aaltonen et al., Eur. J. Pharm. Biopharm. 71 (1), 23–37 (2009).

For additional insight on screening strategies in solid-state chemistry, see http://pharmtech.findpharma.com/pharmtech/Ingredients/Polymorph-Screening-Strategies-A-QampA-with-Jan-Ol/ArticleStandard/Article/detail/647428.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here